Silo Pharma, Inc. (SILO) is making headlines with its strategic move into artificial intelligence, acquiring assets from Qwikagents.ai to bolster its capabilities in deploying autonomous AI agents. This expansion marks a significant pivot for the developmental-stage biopharmaceutical company, which is traditionally focused on treating stress-induced psychiatric disorders and chronic pain. The AI agent market is projected to grow substantially, reaching between $47 billion and $53 billion by 2030, presenting a lucrative opportunity for Silo.
This diversification into AI comes at a time when tech-driven solutions are increasingly pivotal in various sectors, including healthcare. However, Silo’s stock has faced volatility, closing at $0.56 and dropping further in after-hours trading to $0.52, reflecting investor caution amid this transition.
For market professionals, Silo’s foray into AI could signal a shift in its business model, potentially impacting its long-term growth trajectory and stock performance as it seeks to capitalize on the booming AI market.
Source: nasdaq.com